Dystroglycan-sarcoglycan-sarcospan complex (SG-SSPN complex)

The Dystroglycan-sarcoglycan-sarcospan complex is a critical structural assembly located within the sarcolemma of skeletal and cardiac muscle cells (UniProt P18527, Q16586). It functions as a mechanical bridge that links the extracellular matrix, specifically laminin, to the intracellular cytoskeleton via dystrophin, thereby protecting the muscle membrane from contraction-induced injury (Ozawa et al., 2005). Alpha-dystroglycan serves as the primary extracellular receptor for laminin-2, while the sarcoglycan-sarcospan sub-complex provides essential stability to the entire transmembrane assembly (Crosbie et al., 1999). Deficiencies or mutations in the components of this complex lead to various muscular dystrophies, including Limb-Girdle Muscular Dystrophies (LGMD) and Duchenne Muscular Dystrophy (DMD), where the loss of structural integrity results in progressive muscle fiber necrosis (PubMed: 16168378). Current therapeutic approaches primarily involve gene replacement therapies, such as SRP-9003, which utilize adeno-associated virus (AAV) vectors to restore functional sarcoglycan proteins (Sarepta Therapeutics, 2023). Additionally, research into upregulating sarcospan is being explored as a method to stabilize the sarcolemma and compensate for the loss of other complex members (PubMed: 21170023). These therapies aim to reduce serum creatine kinase levels and improve motor function in patients with specific genetic defects (ClinicalTrials.gov: NCT03652259). Safety concerns for these treatments include potential immune reactions to the viral vector or the newly expressed protein, as well as liver toxicity (PubMed: 34151315).

Other names

Sarcoglycan-sarcospan complexSG-SSPN complexDystrophin-associated glycoprotein complex (DGC) componentsDystroglycan complex

Gene replacement therapy to restore functional protein subunits and stabilize the sarcolemma membrane; upregulation of compensatory proteins like sarcospan to mitigate mechanical stress.